Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CMV TCR Gene Therapy: A Phase I Safety, Toxicity and Feasibility Study of Adoptive Immunotherapy With CMV TCR-transduced Donor-derived T Cells for Recipients of Allogeneic Haematopoietic Stem Cell Transplantation

NCT02988258 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT02988258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02988258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CMV TCR Gene Therapy: A Phase I Safety, Toxicity and Feasibility Study of Adoptive Immunotherapy With CMV TCR-transduced Donor-derived T Cells for Recipients of Allogeneic Haematopoietic Stem Cell Transplantation
Lead sponsor
University College, London
Phase
Phase 1
Overall status
Suspended
Start date
July 31, 2013
Completion date
August 31, 2019
Enrollment
10 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cmv infection, haematological malignancies